Adimab
PrivateLast Round
Secondary
Feb 6, 2015
Est. Valuation
$1.1B
Total Funding Raised
$30.8M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Adimab is a biotechnology company that provides a proprietary yeast-based platform for the discovery, maturation, and engineering of therapeutic human antibodies for pharmaceutical and biotechnology partners.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Adimab Comparables
Compare Adimab with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbCellera | 84% | |
| Alloy Therapeutics | 82% | |
| OmniAb Inc. | 81% | |
Adimab Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Secondary | Feb 6, 2015 | ||||
| Series F | Apr 3, 2012 | ||||
| Series E | Nov 22, 2010 | ||||
| Series D | Oct 1, 2009 | ||||
| Series C | Nov 20, 2008 | ||||
Series B | Mar 25, 2008 |
Key People
Founding team and executive leadership
Adimab Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series C, Series D, Series F, Series E, Series A, Series B |
| GV | Series F, Series E, Series D |
| InterWest Partners | Series C |
| Fidelity Management & Research Company | Secondary |
| OrbiMed | Series C, Series D, Series F, Series E |
| Endeavor Venture Funds | Series C |
| Fidelity Investments | Secondary |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 18, 2026
Therapeutic candidate completed Phase 1a trial with partner Gates MRI.
- Mar 18, 2026
Partnered with Gates MRI to design a therapeutic candidate.
Adimab Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Adimab's valuation, stock price, and market status.